Dong-A, Asahi Kasei join forces over Flivas

Published: 2009-04-17 06:56:00

Updated: 2009-04-17 06:56:00

Dong-A Pharmaceutical announced on April 15 that it has entered into an exclusive license agreement Asahi Kasei Pharma in Japan, granting Dong-A to develop and sales of naftopidil, an agent for the treatment of benign prostatic hyperplasia (BPH) marketed as Flivas in Korea.

According to Dong-A...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK